ABIOMED (NASDAQ: ABMD) and Cytosorbents Corporation (NASDAQ:CTSO) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitabiliy, valuation, earnings, institutional ownership and risk.

Volatility & Risk

ABIOMED has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500. Comparatively, Cytosorbents Corporation has a beta of -0.45, suggesting that its share price is 145% less volatile than the S&P 500.

Valuation and Earnings

This table compares ABIOMED and Cytosorbents Corporation’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
ABIOMED $445.30 million 14.03 $97.93 million $1.16 123.61
Cytosorbents Corporation $10.83 million 9.47 -$10.77 million ($0.44) -8.30

ABIOMED has higher revenue and earnings than Cytosorbents Corporation. Cytosorbents Corporation is trading at a lower price-to-earnings ratio than ABIOMED, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

91.0% of ABIOMED shares are owned by institutional investors. Comparatively, 8.8% of Cytosorbents Corporation shares are owned by institutional investors. 10.0% of ABIOMED shares are owned by insiders. Comparatively, 5.6% of Cytosorbents Corporation shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares ABIOMED and Cytosorbents Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ABIOMED 11.70% 12.67% 10.66%
Cytosorbents Corporation -108.69% -1,426.21% -110.58%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for ABIOMED and Cytosorbents Corporation, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ABIOMED 0 0 6 0 3.00
Cytosorbents Corporation 0 0 6 0 3.00

ABIOMED currently has a consensus price target of $152.00, indicating a potential upside of 6.00%. Cytosorbents Corporation has a consensus price target of $12.38, indicating a potential upside of 239.04%. Given Cytosorbents Corporation’s higher probable upside, analysts plainly believe Cytosorbents Corporation is more favorable than ABIOMED.

Summary

ABIOMED beats Cytosorbents Corporation on 10 of the 11 factors compared between the two stocks.

ABIOMED Company Profile

ABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart. The Company’s product portfolio includes the Impella 2.5, Impella CP, Impella RP, Impella LD, Impella 5.0 and AB5000. The Company’s products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists, the electrophysiology lab, the hybrid lab and in the heart surgery suite by heart surgeons.

Cytosorbents Corporation Company Profile

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company’s CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others.

Receive News & Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related companies with MarketBeat.com's FREE daily email newsletter.